Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma

Alexander Parker, Christine M. Lohse, Kevin Wu, Pamela Kreinest, John A III Copland, Tracy Hilton, Michael Wehle, John C. Cheville, Michael Blute

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Loss of expression of the transforming growth factor β type II receptor (TβRII) has been implicated as an important event in renal carcinogenesis; however, its role as a potential prognostic factor remains poorly understood. Using archived tumor samples and long-term follow-up on a cohort of 280 clear cell renal cell carcinoma (ccRCC) patients treated with surgery from 1980 to 1998, we evaluated the association of TβRII expression and cancer-specific survival in both a univariate and multivariate setting. Low tumor expression of TβRII is associated with a less aggressive tumor phenotype at time of surgery. Moreover, those patients with lower levels of TβRII expression experience better cancer-specific survival than patients with higher levels of TβRII expression (log rank P = .034). Based on a Cox proportional hazard model adjusting for age, patients with tumors showing low (hazard ratio, 0.49; 95% confidence interval, 0.27-0.88) and moderate (hazard ratio, 0.7; 95% confidence interval, 0.40-1.23) TβRII expression are at decreased risk of RCC death compared with patients with tumors having high levels of TβRII expression. Adjustment for well-known pathologic predictors of RCC outcome attenuates the association of TβRII expression and ccRCC survival. Of interest, the association with TβRII expression appears more pronounced among those patients with tumors showing less aggressive phenotypes. Data from this investigation are the first to suggest that loss of TβRII expression is associated with improved ccRCC patient survival, especially among those patients with less aggressive disease profiles at time of surgery.

Original languageEnglish (US)
Pages (from-to)453-461
Number of pages9
JournalHuman Pathology
Volume38
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Renal Cell Carcinoma
Phenotype
Survival
Neoplasms
Proteins
Confidence Intervals
Growth Factor Receptors
transforming growth factor-beta type II receptor
Transforming Growth Factors
Proportional Hazards Models
Cell Survival
Carcinogenesis
Kidney

Keywords

  • Cohort
  • Renal cancer
  • Survival
  • Transforming growth factor beta type II receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. / Parker, Alexander; Lohse, Christine M.; Wu, Kevin; Kreinest, Pamela; Copland, John A III; Hilton, Tracy; Wehle, Michael; Cheville, John C.; Blute, Michael.

In: Human Pathology, Vol. 38, No. 3, 03.2007, p. 453-461.

Research output: Contribution to journalArticle

@article{0861718804d74b08a24d39e96037a9d3,
title = "Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma",
abstract = "Loss of expression of the transforming growth factor β type II receptor (TβRII) has been implicated as an important event in renal carcinogenesis; however, its role as a potential prognostic factor remains poorly understood. Using archived tumor samples and long-term follow-up on a cohort of 280 clear cell renal cell carcinoma (ccRCC) patients treated with surgery from 1980 to 1998, we evaluated the association of TβRII expression and cancer-specific survival in both a univariate and multivariate setting. Low tumor expression of TβRII is associated with a less aggressive tumor phenotype at time of surgery. Moreover, those patients with lower levels of TβRII expression experience better cancer-specific survival than patients with higher levels of TβRII expression (log rank P = .034). Based on a Cox proportional hazard model adjusting for age, patients with tumors showing low (hazard ratio, 0.49; 95{\%} confidence interval, 0.27-0.88) and moderate (hazard ratio, 0.7; 95{\%} confidence interval, 0.40-1.23) TβRII expression are at decreased risk of RCC death compared with patients with tumors having high levels of TβRII expression. Adjustment for well-known pathologic predictors of RCC outcome attenuates the association of TβRII expression and ccRCC survival. Of interest, the association with TβRII expression appears more pronounced among those patients with tumors showing less aggressive phenotypes. Data from this investigation are the first to suggest that loss of TβRII expression is associated with improved ccRCC patient survival, especially among those patients with less aggressive disease profiles at time of surgery.",
keywords = "Cohort, Renal cancer, Survival, Transforming growth factor beta type II receptor",
author = "Alexander Parker and Lohse, {Christine M.} and Kevin Wu and Pamela Kreinest and Copland, {John A III} and Tracy Hilton and Michael Wehle and Cheville, {John C.} and Michael Blute",
year = "2007",
month = "3",
doi = "10.1016/j.humpath.2006.08.029",
language = "English (US)",
volume = "38",
pages = "453--461",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma

AU - Parker, Alexander

AU - Lohse, Christine M.

AU - Wu, Kevin

AU - Kreinest, Pamela

AU - Copland, John A III

AU - Hilton, Tracy

AU - Wehle, Michael

AU - Cheville, John C.

AU - Blute, Michael

PY - 2007/3

Y1 - 2007/3

N2 - Loss of expression of the transforming growth factor β type II receptor (TβRII) has been implicated as an important event in renal carcinogenesis; however, its role as a potential prognostic factor remains poorly understood. Using archived tumor samples and long-term follow-up on a cohort of 280 clear cell renal cell carcinoma (ccRCC) patients treated with surgery from 1980 to 1998, we evaluated the association of TβRII expression and cancer-specific survival in both a univariate and multivariate setting. Low tumor expression of TβRII is associated with a less aggressive tumor phenotype at time of surgery. Moreover, those patients with lower levels of TβRII expression experience better cancer-specific survival than patients with higher levels of TβRII expression (log rank P = .034). Based on a Cox proportional hazard model adjusting for age, patients with tumors showing low (hazard ratio, 0.49; 95% confidence interval, 0.27-0.88) and moderate (hazard ratio, 0.7; 95% confidence interval, 0.40-1.23) TβRII expression are at decreased risk of RCC death compared with patients with tumors having high levels of TβRII expression. Adjustment for well-known pathologic predictors of RCC outcome attenuates the association of TβRII expression and ccRCC survival. Of interest, the association with TβRII expression appears more pronounced among those patients with tumors showing less aggressive phenotypes. Data from this investigation are the first to suggest that loss of TβRII expression is associated with improved ccRCC patient survival, especially among those patients with less aggressive disease profiles at time of surgery.

AB - Loss of expression of the transforming growth factor β type II receptor (TβRII) has been implicated as an important event in renal carcinogenesis; however, its role as a potential prognostic factor remains poorly understood. Using archived tumor samples and long-term follow-up on a cohort of 280 clear cell renal cell carcinoma (ccRCC) patients treated with surgery from 1980 to 1998, we evaluated the association of TβRII expression and cancer-specific survival in both a univariate and multivariate setting. Low tumor expression of TβRII is associated with a less aggressive tumor phenotype at time of surgery. Moreover, those patients with lower levels of TβRII expression experience better cancer-specific survival than patients with higher levels of TβRII expression (log rank P = .034). Based on a Cox proportional hazard model adjusting for age, patients with tumors showing low (hazard ratio, 0.49; 95% confidence interval, 0.27-0.88) and moderate (hazard ratio, 0.7; 95% confidence interval, 0.40-1.23) TβRII expression are at decreased risk of RCC death compared with patients with tumors having high levels of TβRII expression. Adjustment for well-known pathologic predictors of RCC outcome attenuates the association of TβRII expression and ccRCC survival. Of interest, the association with TβRII expression appears more pronounced among those patients with tumors showing less aggressive phenotypes. Data from this investigation are the first to suggest that loss of TβRII expression is associated with improved ccRCC patient survival, especially among those patients with less aggressive disease profiles at time of surgery.

KW - Cohort

KW - Renal cancer

KW - Survival

KW - Transforming growth factor beta type II receptor

UR - http://www.scopus.com/inward/record.url?scp=33846858645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846858645&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2006.08.029

DO - 10.1016/j.humpath.2006.08.029

M3 - Article

C2 - 17188329

AN - SCOPUS:33846858645

VL - 38

SP - 453

EP - 461

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 3

ER -